Aktis Oncology, Inc.
NMS: AKTSLive Quote
About Aktis Oncology, Inc.
Healthcare
Biotechnology
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
📊 Fundamental Analysis
Aktis Oncology, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 100.4% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -29.4%, which indicates that capital utilization is currently under pressure.
At a current price of $16.88, AKTS currently trades near the bottom of its 52-week range (15%), indicating potential value or weakness (Range: $14.72 - $29.16).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
Key Financials
Market Cap
$1.04B
Trailing P/E
--
Forward P/E
-10.15
Beta (5Y)
--
52W High
$29.16
52W Low
$14.72
Avg Volume
363K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App